EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Journal of Hepatology, Journal Year: 2018, Volume and Issue: 69(1), P. 182 - 236

Published: April 6, 2018

Language: Английский

---

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet, Journal Year: 2016, Volume and Issue: 389(10064), P. 56 - 66

Published: Dec. 5, 2016

Language: Английский

---

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

The Lancet, Journal Year: 2012, Volume and Issue: 381(9863), P. 303 - 312

Published: Nov. 21, 2012

Language: Английский

---

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Chemical Reviews, Journal Year: 2016, Volume and Issue: 116(2), P. 422 - 518

Published: Jan. 12, 2016

ADVERTISEMENT RETURN TO ISSUEPREVReviewNEXTNext Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials Major Pharmaceutical Companies: New Structural Trends and Therapeutic AreasYu Zhou†, Jiang Wang†, Zhanni Gu†, Shuni Wei Zhu†, José Luis Aceña*‡§, Vadim A. Soloshonok*‡∥, Kunisuke Izawa*⊥, Hong Liu*†View Author Information† Key Laboratory Receptor Research, Shanghai Institute Materia Medica, Chinese Academy Sciences, 555 Zu Chong Zhi Road, 201203, China‡ Department Organic Chemistry I, Faculty Chemistry, University the Basque Country UPV/EHU, Paseo Manuel Lardizábal 3, 20018 San Sebastián, Spain§ Autónoma Madrid, Cantoblanco, 28049 Spain∥ IKERBASQUE, Foundation for Science, María Díaz de Haro 48013 Bilbao, Spain⊥ Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, Japan 533-0024*E-mail: [email protected]*E-mail: protected]Cite this: Chem. Rev. 2016, 116, 2, 422–518Publication Date (Web):January 12, 2016Publication History Received6 July 2015Published online12 January 2016Published inissue 27 2016https://pubs.acs.org/doi/10.1021/acs.chemrev.5b00392https://doi.org/10.1021/acs.chemrev.5b00392review-articleACS PublicationsCopyright © 2016 American Chemical SocietyRequest reuse permissionsArticle Views31495Altmetric-Citations2070LEARN ABOUT THESE METRICSArticle Views are COUNTER-compliant sum full text article downloads since November 2008 (both PDF HTML) across all institutions individuals. These metrics regularly updated to reflect usage leading up last few days.Citations number other articles citing this article, calculated by Crossref daily. Find more information about citation counts.The Altmetric Attention Score is a quantitative measure attention that research has received online. Clicking on donut icon will load page at altmetric.com with additional details score social media presence given article. how calculated. Share Add toView InAdd Full Text ReferenceAdd Description ExportRISCitationCitation abstractCitation referencesMore Options onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Chemical structure,Fluorine,Inhibitors,Pharmaceuticals,Reaction products Get e-Alerts

Language: Английский

---

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Hepatology International, Journal Year: 2017, Volume and Issue: 11(4), P. 317 - 370

Published: June 15, 2017

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with majority all cases worldwide found Asia–Pacific region, where HCC one leading public health problems. Since "Toward Revision Asian Pacific Association for Study Liver (APASL) Guidelines" meeting held at 25th annual conference APASL Tokyo, newest guidelines treatment published by has been discussed. This latest recommend evidence-based management and are considered suitable universal use which a diversity medical environments.

Language: Английский

---

Molecular therapies and precision medicine for hepatocellular carcinoma

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 15(10), P. 599 - 616

Published: July 30, 2018

Language: Английский

---

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

The Lancet, Journal Year: 2012, Volume and Issue: 381(9863), P. 295 - 302

Published: Nov. 22, 2012

Language: Английский

---

The ErbB/HER family of protein-tyrosine kinases and cancer

Pharmacological Research, Journal Year: 2013, Volume and Issue: 79, P. 34 - 74

Published: Nov. 21, 2013

Language: Английский

---

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: May 31, 2021

Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since first tyrosine kinase inhibitor imatinib was approved enter market by US Food Drug Administration (FDA) 2001, an increasing number of small-molecule been developed for treatment malignancies. By December 2020, 89 antitumor FDA National Medical Products (NMPA) China. Despite great progress, anti-cancer still face many challenges, such as a low response rate drug resistance. To better promote development we conducted comprehensive review according target classification. We present all well important candidates clinical trials each target, discuss current provide insights perspectives research drugs.

Language: Английский

---

Ten years of anti-vascular endothelial growth factor therapy

Nature Reviews Drug Discovery, Journal Year: 2016, Volume and Issue: 15(6), P. 385 - 403

Published: Jan. 18, 2016

Language: Английский

---